Journal
CANCER CELL
Volume 22, Issue 5, Pages 631-644Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2012.09.021
Keywords
-
Categories
Funding
- Howard Hughes Medical Institute
- National Institutes of Health [CA104838, CA097323, CA97323, CA105463, 1F32CA137988]
- National Natural Science Foundation of China [81171928]
Ask authors/readers for more resources
Oncogenic Myc alters mitochondrial metabolism, making it dependent on exogenous glutamine (Gln) for cell survival. Accordingly, Gln deprivation selectively induces apoptosis in MYC-overexpressing cells via unknown mechanisms. Using MYCN-amplified neuroblastoma as a model, we identify PUMA, NOXA, and TRB3 as executors of Gln-starved cells. Gln depletion in MYC-transformed cells induces apoptosis through ATF4-dependent, but p53-independent, PUMA and NOXA induction. MYC-transformed cells depend on both glutamate-oxaloacetate transaminase and glutamate dehydrogenase to maintain Gln homeostasis and suppress apoptosis. Consequently, either ATF4 agonists or glutaminolysis inhibitors potently induce apoptosis in vitro and inhibit tumor growth in vivo. These results reveal mechanisms whereby Myc sensitizes cells to apoptosis, and validate ATF4 agonists and inhibitors of Gin metabolism as potential Myc-selective cancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available